Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
QuintilesIMS
AstraZeneca
Boehringer Ingelheim
Farmers Insurance
Federal Trade Commission
Medtronic
Novartis
Fuji

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,856,346

« Back to Dashboard

Which drugs does patent 5,856,346 protect, and when does it expire?

Patent 5,856,346 protects CLEVIPREX and is included in one NDA.

This patent has forty patent family members in thirty countries.
Summary for Patent: 5,856,346
Title: Short-acting dihydropyridines
Abstract:Compounds of the general formula ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, chloro, bromo, nitro, cyano, trifluoromethyl, and R.sub.3 and R.sub.4 are independently selected from straight or branched lower (1-5 carbon atoms) alkyl groups, and including all optical isomers, provided that when R.sub.3 is methyl and R.sub.4 is tert.-butyl, then R.sub.1 /R.sub.2 are not hydrogen/hydrogen, hydrogen/2'-trifluormethyl, 2'-chloro/3'-chloro, and when R.sub.3 is methyl and R.sub.1 /R.sub.2 is hydrogen/3'-nitro, then R.sub.4 are not methyl, ethyl, propyl, iso-propyl, tert.-butyl, processes for their preparation, pharmaceutical preparations containing them and the use of the compounds in lowering the blood pressure.
Inventor(s): Andersson; Kjell Hjalmar (Fjar.ang.s, SE), Nordlander; Margareta (Askim, SE), Westerlund; Rolf Christer (Molndal, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Application Number:08/356,224
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 5,856,346

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-001 Aug 1, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE ➤ Subscribe
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-002 Aug 1, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE ➤ Subscribe
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-003 Nov 8, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,856,346

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9303657Nov 05, 1993
PCT Information
PCT FiledNovember 03, 1994PCT Application Number:PCT/SE94/01031
PCT Publication Date:May 11, 1995PCT Publication Number: WO95/12578

International Patents Family Members for US Patent 5,856,346

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Czech Republic 9601273 ➤ Subscribe
Czech Republic 285691 ➤ Subscribe
Germany 69425152 ➤ Subscribe
Denmark 0726894 ➤ Subscribe
Estonia 03230 ➤ Subscribe
Egypt 20539 ➤ Subscribe
European Patent Office 0726894 ➤ Subscribe C300520 Netherlands ➤ Subscribe
European Patent Office 0726894 ➤ Subscribe 1290008-0 Sweden ➤ Subscribe
European Patent Office 0726894 ➤ Subscribe C00726894/01 Switzerland ➤ Subscribe
European Patent Office 0726894 ➤ Subscribe 12C0053 France ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Farmers Insurance
Fuji
Cipla
Covington
US Army
QuintilesIMS
Julphar
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot